Ileal pouch-anal anastomosis (IPAA) is the procedure of choice for most patients with ulcerative colitis (UC) requiring proctocolectomy. '-5 Despite this IPAA is associated with significant morbidity both in the early postoperative period as well as in the longer term.1 [4] [5] [6] The most significant longterm complication is pouchitis.' [7] [8] [9] [10] [11] The reported incidence varies from 7-45% depending on definition and particularly on whether histological confirmation is required.0- 15 Pouchitis is characterised by an increase in frequency of stools with occasional blood and mucus and general malaise. These symptoms often respond well to antibiotics. However, some patients with pouchitis develop recurrent or chronic symptoms that may require prolonged medical treatment including corticosteroids.' 7 10 The aetiology of pouchitis is unknown. It occurs almost exclusively in patients who previously had UC, which suggests that it may represent recurrent inflammation similar to the original disease in ileal mucosa that has undergone colonic metaplasia.9 Other possible causes for pouchitis include bacterial overgrowth16-18 and changed bile acid metabolism,8 ischaemia19-21 and in some cases unrecognised Crohn's disease.
Chronic inflammation and colonic metaplasia occur in all pouches regardless of the original indication for IPAA. The key histological features of colonic metaplasia include loss of villous height with compensatory crypt elongation and a raised crypt cell proliferation rate (CCPR)." 15 These changes occur soon after ileostomy closure with the resumption of faecal stream (and stasis) within the pouch.'5 The significance of colonic metaplasia is largely unknown. It may represent a useful adaptive response with improved (colon-like) barrier function to the new luminal environment but may also predispose susceptible subjects to pouchitis.14 Barrier function may be assessed in vivo by measuring permeation of different molecular weight probes across the intestinal wall. These probes have been used to study the increased permeability of mucosa seen in different disease states. In this study, methodology using 51Chromium-EDTA (51Cr-EDTA) as a probe was adapted to assess barrier function in IPAA. [22] [23] [24] [25] The aim of this study was to assess barrier function (as measured by 51Cr-EDTA permeability) in IPAA before and after ileostomy closure and with pouchitis. Rectal permeability in active and inactive UC was measured as an indication of relative barrier function to IPAA. Finally a pilot study was undertaken to assess the hypothesis that nicotine improves barrier function in IPAA.
Methods

Patients
Twelve patients awaiting ileostomy closure, eight patients with pouchitis, and 14 patients with healthy functioning pouches were assessed. All Administration of dose A 10 cm Quill (Southern Syringe Services, Dudley, UK) was introduced per anus into the pouch/rectum with the patient in the left lateral position. Two ml of isotonic saline were administered to ensure correct positioning. The 4 ml radioactive sample was instilled followed by a further 4 ml of isotonic saline to minimise residual radioactivity in the Quill. Patients remained prone for 20 minutes and were encouraged to drink 500 ml of fluid to ensure an adequate urine output. No pouch evacuation was permitted for four hours after administration of 51Cr-EDTA. Urine collection continued for 24 hours.
Sample preparation and measurement The 24 hour urine volume was recorded and lxO 1 ml aliquots taken for assay. The urine aliquots and standards were counted within 24 hours using a well type gammacounter (LKB 1260 Multigamma II). A 20 ml aliquot of urine was stored at -20C for subsequent creatinine assay.
Patientfollow up Patients were endoscoped immediately after urine collection with pouch or rectal biopsy specimens being taken. Paraffin wax sections were stained routinely with haematoxylin and eosin as well as with high iron diamine-alcian blue as previously described. 27 The sections were scored for mucin (1=sialomucin only, 2=predominant sialomucin, 3=predominant sulphomucin, and 4=sulphomucin only) and for the degree of villous atrophy.14 Eight patients awaiting ileostomy closure were assessed on a second occasion. Of these, four had taken transdermal nicotine for four weeks and a control group had no intervention. Statistics Group comparisons were made using the Wilcoxon rank test for non-parametric data. The significance of association was assessed by means of Spearman's rank correlation.
Results
Permeability as assessed by urinary recovery of 51Cr-EDTA showed pronounced differences (Table I, Fig 1) . There was lower permeability in the healthy pouches more than 12 months after ileostomy closure compared with healthy pouches in the first 12 months but the difference was not significant (p=0 1) and so healthy pouches were combined as one group. Villous atrophy Permeability was significantly higher in preclosure pouches compared with healthy pouches (p<0 002). Pouchitis was associated with higher permeability than for a healthy pouch (p-OOO6) but did not achieve preclosure levels. The permeability of healthy pouch and quiescent UC was similar (p=0-12). Active UC produced higher permeability levels than pouchitis (p.0.02). Histological scores of villous height and mucin histochemistry for the three IPAA groups are shown (Table II) . A significant loss of villous height is seen from preclosure to healthy pouches (p-0O009) and from healthy pouches to pouchitis (p-0 02). A partial switch to sulphomucin is seen in healthy pouches (p<005) compared with preclosure, however, this was less noticeable in pouchitis mucosa. There was a significant correlation between permeability score and histological grades. A scattergram comparing all three groups (preclosure, healthy pouch, and pouchitis) shows a significant negative correlation between 51Cr-EDTA recovery and villous atrophy (r=-0367, p=003) (Fig 2) and mucin score (r=-0.34, p=005) (Fig 3) . The significance is increased if the pouchitis group is excluded for both villous atrophy (r=-0.65, p=00003) and mucin (r=-0-48, p=0.01).
Inflammation as assessed by a histology index26 is listed in Table III . Pouchitis biopsy specimens were significantly more inflammed than preclosure pouch (p=0.09). Preclosure pouch scores were higher for inflammation than healthy pouch, however, the difference was not significant (p=0Q07).
Discussion
Intestinal epithelium has conflicting functions.
It permits absorption of nutrients, ions, and water while acting as a barrier to prevent 25 29 IPAA is a useful model for assessing intestinal adaptation to a new luminal environment. Ileal epithelium before surgery is predominantly absorptive with long villi to increase the total surface area in contact with luminal content. This is reflected in the high values of 51Cr-EDTA permeability in preclosure ileal pouch reported in this study. At the completion of surgery the ileal pouch (neorectum) takes on a reservoir function. The histological changes in pouch epithelium are well described1012 14 15 18 The significance of such changes and particularly whether functional adaptation occurs with respect to barrier function has not previously been reported. Before assessing the results of this study several criticisms of the methodology need to be considered. Although patients evacuated before instillation of 51Cr-EDTA it is possible that some of the reduction of urinary recovery of 51Cr-EDTA from functioning pouches is due to dilution of the probe in residual faecal effluent. This is probably not an important factor as preliminary experiments using pouch washouts with isotonic saline versus evacuation alone did not significantly increase urinary recovery of 51Cr-EDTA. Another problem relates to completeness of urine collection. To minimise this a creatinine clearance was measured and if <1.5 ml/sec the patient was excluded. At the end of the study only one exclusion (a patient with inactive UC) was necessary. The degree of inflammation as assessed by histology was higher in the preclosure group than healthy pouch (p=007), which may account for some of the difference between the two groups. Finally, no assumptions regarding macromolecule/antigen absorption can be made from studies using these comparatively small probes. No permeability for healthy pouch and inactive UC suggests that the functional adaptation in the ileal pouch is almost complete despite variable degrees of histological colonic metaplasia. Although this is the first permeability study of ileal pouch adaptation much work has been published on the adaptation of small bowel mucosa in the blind loop syndrome.32 33 Using self filling blind loops of rat jejunum Schulzke et al were able to show an increase in epithelial resistance from 8±1 to 23 ± 3/cm2 (Ussing chamber) in mucosa from the 'blind loop'. Ultrastructural study of the adapted mucosa showed an increase in depth of crypt tight junctions. 32 The increase in permeability in pouchitis compared with healthy pouch (Table I, Fig 1) is not surprising. Increased small intestinal permeation of 51Cr-EDTA has been reported in small bowel inflammation for both Crohn's disease34-36 and coeliac disease.37 38 The increase in permeability is probably due to a variety of factors including breaches in the epithelial barrier (ulcers), transepithelial migration of polymorphonuclear cells,39 and soluble mediators, for example, PAF, y interferon.40 It is of interest that permeability to 51Cr-EDTA in pouchitis was significantly lower than for active UC. This suggests that the inflammation in pouchitis is not as severe or that pouchitis may be a fundamentally different process to UC. The two patients with the highest permeability in the pouchitis group (Fig 1) were the only patients with extraintestinal manifestations. One patient had arthritis, pyoderma, and erythema nodosum (19.5% 51Cr-EDTA) and the other patient had arthritis (8.5% 51Cr-EDTA). Although anecdotal, it supports the concept that reduced barrier function to luminal content may be important in the pathogenesis of extraintestinal manifestations of inflammatory bowel disease.41 42 A small unblinded control study assessing the effect of transdermal nicotine on preclosure ileal pouch permeability was performed in eight patients. Although these data should be regarded as preliminary a pronounced reduction in permeability was seen in the patients treated with nicotine. In support of this Prytz et al have reported a reduced small intestinal permeability in smokers.43 This effect on epithelial barrier function may account for the reduced incidence of UC44-46 and pouchitis47 in smokers. Barrier function is likely to be particularly important in the period immediately after ileostomy closure. At this time the absorptive (highly permeable) ileum is exposed to a large quantity of potential antigens and toxins. Exposure to the mucosal immune system in susceptible patients may initiate pouchitis. This is supported by the finding that pouchitis occurs on average 3-5 months after ileostomy closure.'0 It is in this early period that augmentation of barrier function by smoking/nicotine may be important in the subsequent reduction of pouchitis. This is of course highly speculative and it will be important to confirm the early findings reported in this study. If correct a controlled trial of nicotine for the six months after ileostomy closure would be worthwhile particularly with regard to early pouch function and in the longer term prevention of pouchitis.
